[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tumor-immunity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tumor-immunity":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100580961","application-of-68ga-labeled-cd73-targeting-probe-petct-imaging-in-the-diagnosis-of-malignant-tumor-100580961",false,"NCT06844110","Application of 68GA-labeled CD73 Targeting Probe PET\u002FCT Imaging in the Diagnosis of Malignant Tumor","Inclusion Criteria:\n\n* 1: Age: ≥18 years, expected survival ≥12 weeks 2: Without radiotherapy and chemotherapy, surgery or biopsy is feasible to obtain pathological diagnosis 3: Standard Solid Tumor Response Evaluation Criteria (RECIST) version 1.1 with at least one measurable target lesion 4: Obtain written informed consent and be able to follow up\n\nExclusion Criteria:\n\n\\- 1: Severe liver and kidney dysfunction. 2: Women who are planning to conceive, pregnant, or breastfeeding, as well as those planning to have children during the study period, are not eligible to participate in this research. Women of childbearing potential must use effective contraception throughout the course of the study.\n\n3: Individuals unable to lie flat for thirty minutes. 4: Suffers from claustrophobia or other mental illnesses 5: Researchers believe that the subject has other conditions that make them unsuitable for inclusion in this study 6: Refuses to join this clinical study",true,"ALL","18 Years","70 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","68Ga-DOTA-dPNE PET\u002FCT imaging was performed on patients with malignant tumors to observe the binding of lesions with the tracer and evaluate the expression of CD73. At the same time, correlation analysis was performed combined with relevant clinical indicators to evaluate the efficacy of 68Ga-DOTA-dPNE in the diagnosis and guidance of malignant tumor patients, and predict the response of targeted therapy.",[27],"Tumor Immunity","RECRUITING","2025-07-31",{"date":31,"type":32},"2025-08-05","ACTUAL",{"date":34,"type":32},"2025-03-01",{"date":36,"type":21},"2026-03-30",{"name":38,"class":39},"Peking Union Medical College Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":40},"100374075","phase-2-rfa-plus-carrizumab-vs-carrizumab-alone-for-hcc-100374075","NCT04150744","RFA Plus Carrizumab vs Carrizumab Alone for HCC","Radiofrequency Ablation Plus Carrizumab vs Carrizumab Alone for Moderate or Advanced Hepatocellular Carcinoma: A Real World Study","Inclusion Criteria:\n\n1. Age from 18-75 years\n2. Diagnosis as hepatocellular carcinoma from histology and cytology\n3. BCLC B-C degree\n4. Score of ECOG PS: 0-2\n5. Child-Pugh Score: A or B\n6. Not suitable for resection or liver transplantation\n7. Have not received systemic therapy\n8. Have at least one evaluable target mass from CT or MRI according to mRECIST\n9. The estimated survival time ≥ 12 weeks\n10. Patients with HBV infection having HBV-DNA \\\u003C500IU\u002FmL and standard anti-virus treatment. Patients with HCV infection must receive standard anti-virus treatment.\n11. The function of main organs normal\n12. Sign informed consent\n\nExclusion Criteria:\n\n1. Have cholangiocarcinoma, mixed type of hepatocarcinoma and fibrolamellar hepatocellular carcinoma. Have incurable malignant tumor in five years.\n2. Have local ablation, TACE or radiotherapy in 3 months before enrolled.\n3. Prepared to or have received organic or bone marrow transplantation.\n4. Uncontrollable ascites, hepatic encephalopathy or esophageal and gastric varices.\n5. Have hypertension and can't lower down to the normal level using blood pressure medication.\n6. Have type II myocardial ischemia or myocardial infarction, uncontrollable arrhythmia.\n7. Have diseases to influent the effect of oral drugs, for example, unable to swallow, chronic diarrhea and intestinal obstruction.\n8. Have gastrointestinal bleeding in 6 months\n9. Have abdominal fistula, gastrointestinal perforation or abdominal abscess\n10. Patients with lung fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug related pneumonia or severe dysfunction of lung.\n11. Routine urine test showed urinary protein ≥++ or the 24 hours amount of urinary protein ≥1.0 g\n12. Patients have autoimmune disease\n13. Patients need corticosteroid or other immunosuppressant therapy\n14. Patients have anti-tumor vaccine and other immunostimulate anti-tumor drugs in 3 months\n15. Allergy to monocloning antibody\n16. Pregnant or breastfeeding female Other patients not suitable to be enrolled in the study.","75 Years",{"count":50,"type":21},120,[52],"PHASE2","The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS.",[27,55,56],"Immunosuppression","Radiofrequency Ablation",[58,59,60],"RFA","immunosuppressant","hepatocellular carcinoma","2020-07-06",{"date":63,"type":32},"2020-07-08",{"date":65,"type":21},"2020-08-01",{"date":67,"type":21},"2026-12-30",{"name":69,"class":39},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]